Subject:
- Active Substance: Angiotensin II acetate
- Name: Giapreza®
- Therapeutic area: Hypotension
- Pharmaceutical company: PAION Deutschland GmbH
Time table:
- Start: 15.07.2021
- Final decision by G-BA: 06.01.2022
Final decision:
- No additional benefit proved